AstraZeneca’s coronavirus vaccine fared better than expected in a US clinical trial, providing reassurance about its safety and efficacy.
The shot developed with the University of Oxford was 79 per cent effective in preventing Covid-19, and an independent monitoring board found no safety concerns, the company said Monday. All those immunised were protected from severe disease and death in a study of more than 30,000 volunteers.
The findings should bolster confidence in the vaccine after confusion over its efficacy and the best dosing regimen slowed take-up. The product is at the center of a supply showdown with the European Union just days after concerns about blood clots prompted a dozen member states to suspend immunisations. Even after the European Medicines Agency declared it safe last Thursday, not all EU countries have resumed vaccinations.
“Efficacy is better than we had expected,” said Peter Welford, an analyst at Jefferies in London. “Importantly, after recent largely unfounded safety concerns in Europe, the study confirms the safety profile.”
Astra shares rose as much as 1.4 per cent in London trading. The company said it plans to submit the trial data to US regulators in coming weeks, seeking clearance for emergency-use authorisation.
Data Confusion
A shortfall in deliveries to the EU has put Astra at odds with the bloc and led officials to oppose exports of the shot from the region as they seek to hold the company to account. The new data offer more clarity than the first study results released last November. Those clinical trials, conducted in the U.K. and Brazil, produced a range of readings due to different dosing amounts and regimens used. At least 10 EU countries only approved the shot for under-65s initially as early trials lacked older participants. Many have since reversed course after more data from real-world use showed the vaccine was effective for everyone.
Older adults made up about a fifth of the US trial, which showed efficacy of 80 per cent in that age group. The results “offer confidence that adults of all ages can benefit from protection against the virus,” Ann Falsey, a professor at the University of Rochester’s School of Medicine and one of the trial’s lead investigators, said in a statement.
A number of cases involving rare but serious blood clots also damaged the vaccine’s image. The EMA and U.K.’s regulator said Thursday that no definitive link could be established between the clots and the vaccine, and the benefits of its use continued to outweigh the risks. The US trial review that found no safety concerns looked specifically at blood clots.
Easy Storage
Skepticism over the vaccine started last year when Astra and Oxford first reported initial data. At the time, they offered two different efficacy readings of 62 per cent and 90 per cent.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU